TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Telik
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

• 18 years of age or older

• Histologically confirmed non-small cell lung cancer

• Stage IV or IIIB

• Measurable disease by RECIST

• ECOG performance status of 0-1

• Adequate liver and renal function

• Adequate bone marrow reserve

Exclusion Criteria:

• History of bone marrow transplantation or stem cell support

• Pregnant or lactating women